Opgenra

RSS

Withdrawn

This medicine's authorisation has been withdrawn

eptotermin alfa
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 1 July 2016, the European Commission withdrew the marketing authorisation for Opgenra (eptotermin alfa) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Olympus Biotech International Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Opgenra was granted marketing authorisation in the EU on 19 February 2009 for treatment of spondylolisthesis. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2013. 

The European Public Assessment Report (EPAR) for Opgenra is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (709.65 KB - PDF)

Skatīt

español (ES) (582.84 KB - PDF)

Skatīt

čeština (CS) (592.56 KB - PDF)

Skatīt

dansk (DA) (583.5 KB - PDF)

Skatīt

Deutsch (DE) (590.01 KB - PDF)

Skatīt

eesti (ET) (520.97 KB - PDF)

Skatīt

ελληνικά (EL) (661.16 KB - PDF)

Skatīt

français (FR) (524.93 KB - PDF)

Skatīt

italiano (IT) (525.11 KB - PDF)

Skatīt

latviešu (LV) (658.97 KB - PDF)

Skatīt

lietuvių (LT) (552.27 KB - PDF)

Skatīt

magyar (HU) (583.85 KB - PDF)

Skatīt

Malti (MT) (672.79 KB - PDF)

Skatīt

Nederlands (NL) (541.61 KB - PDF)

Skatīt

polski (PL) (667.42 KB - PDF)

Skatīt

português (PT) (537.23 KB - PDF)

Skatīt

română (RO) (553.82 KB - PDF)

Skatīt

slovenčina (SK) (1.03 MB - PDF)

Skatīt

slovenščina (SL) (583.13 KB - PDF)

Skatīt

suomi (FI) (522.19 KB - PDF)

Skatīt

svenska (SV) (521.89 KB - PDF)

Skatīt

Product information

български (BG) (1.87 MB - PDF)

Skatīt

español (ES) (1.2 MB - PDF)

Skatīt

čeština (CS) (1.62 MB - PDF)

Skatīt

dansk (DA) (1.2 MB - PDF)

Skatīt

Deutsch (DE) (1.24 MB - PDF)

Skatīt

eesti (ET) (1.18 MB - PDF)

Skatīt

ελληνικά (EL) (1.92 MB - PDF)

Skatīt

français (FR) (1.22 MB - PDF)

Skatīt

hrvatski (HR) (1.24 MB - PDF)

Skatīt

italiano (IT) (1.21 MB - PDF)

Skatīt

latviešu (LV) (1.62 MB - PDF)

Skatīt

lietuvių (LT) (1.27 MB - PDF)

Skatīt

magyar (HU) (1.64 MB - PDF)

Skatīt

Malti (MT) (1.65 MB - PDF)

Skatīt

Nederlands (NL) (1.24 MB - PDF)

Skatīt

polski (PL) (1.63 MB - PDF)

Skatīt

português (PT) (1.19 MB - PDF)

Skatīt

română (RO) (1.28 MB - PDF)

Skatīt

slovenčina (SK) (2.2 MB - PDF)

Skatīt

slovenščina (SL) (1.57 MB - PDF)

Skatīt

suomi (FI) (1.2 MB - PDF)

Skatīt

svenska (SV) (1.19 MB - PDF)

Skatīt

Íslenska (IS) (1.17 MB - PDF)

Skatīt

norsk (NO) (1.19 MB - PDF)

Skatīt
Latest procedure affecting product information:IG/0473/G
01/07/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (552.36 KB - PDF)

Skatīt

español (ES) (464.84 KB - PDF)

Skatīt

čeština (CS) (544.1 KB - PDF)

Skatīt

dansk (DA) (467.77 KB - PDF)

Skatīt

Deutsch (DE) (464.93 KB - PDF)

Skatīt

eesti (ET) (464.72 KB - PDF)

Skatīt

ελληνικά (EL) (548.15 KB - PDF)

Skatīt

français (FR) (464.43 KB - PDF)

Skatīt

italiano (IT) (464.27 KB - PDF)

Skatīt

latviešu (LV) (543.63 KB - PDF)

Skatīt

lietuvių (LT) (529.55 KB - PDF)

Skatīt

magyar (HU) (507.79 KB - PDF)

Skatīt

Malti (MT) (544.35 KB - PDF)

Skatīt

Nederlands (NL) (464.48 KB - PDF)

Skatīt

polski (PL) (547.05 KB - PDF)

Skatīt

português (PT) (464.65 KB - PDF)

Skatīt

română (RO) (527.4 KB - PDF)

Skatīt

slovenčina (SK) (994.79 KB - PDF)

Skatīt

slovenščina (SL) (476.21 KB - PDF)

Skatīt

suomi (FI) (464.46 KB - PDF)

Skatīt

svenska (SV) (481.49 KB - PDF)

Skatīt

norsk (NO) (622.87 KB - PDF)

Skatīt

български (BG) (818.76 KB - PDF)

Skatīt

español (ES) (499.15 KB - PDF)

Skatīt

čeština (CS) (782.65 KB - PDF)

Skatīt

dansk (DA) (678.87 KB - PDF)

Skatīt

Deutsch (DE) (624.42 KB - PDF)

Skatīt

eesti (ET) (609.17 KB - PDF)

Skatīt

ελληνικά (EL) (817.11 KB - PDF)

Skatīt

français (FR) (700.32 KB - PDF)

Skatīt

italiano (IT) (693.06 KB - PDF)

Skatīt

latviešu (LV) (765.09 KB - PDF)

Skatīt

lietuvių (LT) (722.78 KB - PDF)

Skatīt

magyar (HU) (712.62 KB - PDF)

Skatīt

Malti (MT) (761.19 KB - PDF)

Skatīt

Nederlands (NL) (627.42 KB - PDF)

Skatīt

polski (PL) (840.43 KB - PDF)

Skatīt

português (PT) (699.86 KB - PDF)

Skatīt

română (RO) (732.14 KB - PDF)

Skatīt

slovenčina (SK) (142.87 KB - PDF)

Skatīt

slovenščina (SL) (605.13 KB - PDF)

Skatīt

suomi (FI) (604.16 KB - PDF)

Skatīt

svenska (SV) (481.49 KB - PDF)

Skatīt

norsk (NO) (622.87 KB - PDF)

Skatīt

Product details

Name of medicine
Opgenra
Active substance
eptotermin alfa
International non-proprietary name (INN) or common name
eptotermin alfa
Therapeutic area (MeSH)
Spondylolisthesis
Anatomical therapeutic chemical (ATC) code
M05BC02

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.

Authorisation details

EMA product number
EMEA/H/C/000819
Marketing authorisation holder
Olympus Biotech International Limited

Block 2
International Science Centre
National Technology Park
Castletroy
Limerick
Ireland

Marketing authorisation issued
19/02/2009
Withdrawal of marketing authorisation
01/07/2016
Revision
9

Assessment history

This page was last updated on

Share this page